European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

(2016) Marc S. Sabatine et al.   AMERICAN HEART JOURNAL

Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries – Findings from the EUROASPIRE IV survey

(2016) Ž. Reiner et al.   ATHEROSCLEROSIS

Improving prevention: risk scores, imaging, and PCSK9 inhibitors

(2016) Thomas F. Lüscher   EUROPEAN HEART JOURNAL

Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217

(2016) Marianne Benn et al.   EUROPEAN HEART JOURNAL

Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents

(2016) Paul M Ridker et al.   EUROPEAN HEART JOURNAL

2016 European Guidelines on cardiovascular disease prevention in clinical practice

(2016) Massimo F. Piepoli et al.   EUROPEAN HEART JOURNAL

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance

(2016) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia

(2016) Leopoldo Perez de Isla et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data

(2016) Naveed Sattar et al.   Lancet Diabetes & Endocrinology

Impact of Postdischarge Statin Withdrawal on Long-Term Outcomes in Patients With Acute Myocardial Infarction

(2015) Min Chul Kim et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia

(2015) Eliano Pio Navarese et al.   ANNALS OF INTERNAL MEDICINE

Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes

(2015) Baris Gencer et al.   ATHEROSCLEROSIS

Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology

(2015) Guy De Backer et al.   ATHEROSCLEROSIS

Acute and chronic impact of cardiovascular events on health state utilities

(2015) Louis S Matza et al.   BMC HEALTH SERVICES RESEARCH

A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins

(2015) Joseph L. Goldstein et al.   CELL

The Agenda for Familial Hypercholesterolemia

(2015) Samuel S. Gidding et al.   CIRCULATION

Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death

(2015) Henriette Walaas Krogh et al.   EUROPEAN HEART JOURNAL

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

(2015) John J.P. Kastelein et al.   EUROPEAN HEART JOURNAL

Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes

(2015) David Nanchen et al.   EUROPEAN HEART JOURNAL

The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis

(2015) Michael J. Lipinski et al.   EUROPEAN HEART JOURNAL

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

(2015) Marco Roffi et al.   EUROPEAN HEART JOURNAL

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment

(2015) Albert Wiegman et al.   EUROPEAN HEART JOURNAL

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

(2015) Patrick M. Moriarty et al.   Journal of Clinical Lipidology

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial

(2014) Gregory G. Schwartz et al.   AMERICAN HEART JOURNAL

Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: Can we do better? Analysis of results obtained during the past two decades in 1669 French subjects

(2014) S. Béliard et al.   ATHEROSCLEROSIS

PCSK9

(2014) Nabil G. Seidah et al.   CIRCULATION RESEARCH

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

(2014) M. Cuchel et al.   EUROPEAN HEART JOURNAL

An assessment by the Statin Muscle Safety Task Force: 2014 update

(2014) Robert S. Rosenson et al.   Journal of Clinical Lipidology

An assessment by the Statin Intolerance Panel: 2014 update

(2014) John R. Guyton et al.   Journal of Clinical Lipidology

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

(2014) Erik Stroes et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction

(2014) Ron Do et al.   NATURE

Mortality Among Patients With Familial Hypercholesterolemia: A Registry‐Based Study in Norway, 1992–2010

(2014) Liv Mundal et al.   Journal of the American Heart Association

Diagnosis and treatment of familial hypercholesterolaemia

(2013) G. Kees Hovingh et al.   EUROPEAN HEART JOURNAL

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients

(2012) David Sullivan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada

(2011) Anselm K Gitt et al.   European Journal of Preventive Cardiology

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

(2010) Naveed Sattar et al.   LANCET

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

(2008) A. Neil et al.   EUROPEAN HEART JOURNAL